Clinical Trial Update: Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating darolutamide for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING